Advertisement
Advertisement

REPL

REPL logo

Replimune Group, Inc.

12.06
USD
Sponsored
-0.80
-6.22%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

11.97

-0.09
-0.73%

Replimune Group, Inc. Profile

About

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States.

Info & Links

CEO

Sushil Patel

Headquarters

500 Unicorn Park Drive ,Suite 303
WOBURN, MA 01801, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.replimune.com

Auditor

PricewaterhouseCoopers LLP

Share holders

5

Employees

465

Replimune Group, Inc. Statistics

Valuation Measures

Market Capitalization2

1.01B

Enterprise Value

905.04M

Enterprise Value/EBITDA(ttm)

-2.84

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

5.99

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-128.57%

Return on Invested Capital(ttm)

-98.60%

Return on Assets(ttm)

-82.35%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-319.13M

Net Income Available to Common(ttm)

-313.94M

Diluted EPS(ttm)

-3.38

Share Statistics

Beta (5Y Monthly)

0.88

52-Week Change

120.07%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

83.95M

Dividend Yield

0.00%

Float4

79.49M

% Held by Insiders

5.40%

% Held by Institutions

92.53%

Balance Sheet

Total Cash(mrq)

268.89M

Total Cash Per Share(mrq)

3.20

Total Debt(mrq)

108.10M

Total Debt/Equity(mrq)

65.06%

Current Ratio(mrq)

4.79%

Quick Ratio(mrq)

4.79%

Book Value Per Share(mrq)

2.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.02

Free Cash Flow(ytd)

-284.57M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement